Latest news and press releases about Compugen Ltd. (CGEN): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe.
Price
| Price | $2.41 |
| Market Cap | $228M |
| Exchange | NASDAQ |
| Country | IL |
Valuation Ratios
| P/E Ratio | 6.42 |
| Price / Book | 2.57 |
| EV / EBITDA | 6.74 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 42.57% |
| Return on Invested Capital | 26.00% |
| Return on Assets | 25.43% |
| Gross Margin | 86.89% |
| Operating Margin | 40.94% |
| Net Margin | 47.55% |
Related companies: CRBP · CRDF · CYBN · IPHA · MIST · MOLN · NVCT
Explore sector: Healthcare · Biotechnology
More sections of CGEN: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks